12 July 2021 | News
Ms. Kyahn Williamson joins Telix to lead corporate comm and investor relations
Australia's Telix Pharmaceuticals, focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR), announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations.
Kyahn joins Telix from WE Communications, where she was Group Head of Investor and Corporate Communication. Over the past 15 years, Kyahn has worked with a wide range of ASX-listed companies spanning the medtech and biotech sectors, designing and implementing investor relations and public relations strategies, and advising across multiple IPOs and M&A transactions.
Ms. Williamson stated, “I’m absolutely delighted to join the team and apply my deep industry experience to support Telix as it makes the transition to a commercial-stage company focused on delivering unmet patient need. With this transition comes a very distinct set of communications and investor relations needs. I look forward to joining the senior executive to continue to build Telix’s reputation as a global leader in diagnostic and therapeutic applications of molecularly-targeted radiation.”
Telix CEO, Dr. Christian Behrenbruch added, “On behalf of the global team, I am delighted to welcome Kyahn to the business at such a critical juncture. Ky led our IPO communications back in 2017 and with the Company reaching key commercial milestones.”
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.